Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091871 · ClinicalTrials.gov registry record
A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
A clinical trial of Hypereosinophilic Syndrome and Eosinophilia, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT00091871 is a study of Hypereosinophilic Syndrome and Eosinophilia that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 50 participants, below the 126-participant average among 7 other Hypereosinophilic Syndrome trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00091871, a study of Hypereosinophilic Syndrome and Eosinophilia, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Eosinophils are a type of white blood cell. Elevated eosinophil levels can damage the heart, nerves, and other organs, in the syndrome known as hypereosinophilic syndrome (HES). Some individuals have a hereditary form of HES known as familial eosinophilia (FE). More research on the causation and mechanisms of HES is needed in order to design more effective and less toxic therapies. This study will investigate FE and its genetic causes, damage mechanisms, and disease markers (such as blood test abnormalities). It will enroll approximately 50 individuals (both adults and children) from a previously studied family with FE. This is a long-term study of indefinite duration. Participants will undergo yearly clinical examinations including medical history, physical examination, bloodwork, EKG, echocardiogram, and pulmonary function tests, with additional or more frequent examinations and tests as required. In addition, participants will donate blood and tissue for research purposes. Both adult and child participants will donate blood. At the initial evaluation, adult participants will donate bone marrow. During the study, some adult participants will also undergo a limited number of leukaopheresis sessions, in which blood is donated from one arm, the blood is separated into red blood cells and other components, and the red blood cells are returned into the donor's other arm.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2005-06-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00091871
The ClinicalTrials.gov registry entry for NCT00091871 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 126-participant average among 7 other Hypereosinophilic Syndrome trials with a reported enrollment target (60% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypereosinophilic Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT00091871 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00091871 about?
NCT00091871 is a clinical study titled "A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression". Eosinophils are a type of white blood cell. Elevated eosinophil levels can damage the heart, nerves, and other organs, in the syndrome known as hypereosinophilic syndrome (HES). Some individuals have a hereditary form of HES known as familial eosinophilia (FE). More research on the causation and mec...
What is the current status of trial NCT00091871?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2005-06-08.
What conditions does trial NCT00091871 study?
This clinical trial studies the following conditions: Hypereosinophilic Syndrome, Eosinophilia.
Who is sponsoring clinical trial NCT00091871?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00091871 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypereosinophilic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
RECRUITING · Phase 2
-
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
RECRUITING · Phase 3
-
Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents
RECRUITING · Phase 2
-
A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
ACTIVE NOT RECRUITING · Phase 3
-
Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.